Targeting the non-canonical NF-κB pathway through NFKB2 knockdown resulted in the disruption of oncogenic transcriptional programmes shared with myeloma patients displaying high NF-κB activity (NF-κB+), along with the activity of p52-responsive enhancers. This evidence concerns the gene NFKB1 and plasma cell myeloma.